Anti-IL-20 monoclonal antibody alleviates …...2012/09/19 · IL-20 is a proinflammatory cytokine...
Transcript of Anti-IL-20 monoclonal antibody alleviates …...2012/09/19 · IL-20 is a proinflammatory cytokine...
IL-20 and oral cancer 1
Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses
tumor growth
Yu-Hsiang Hsu1, Chi-Chen Wei2, Dar-Bin Shieh3, Chien-Hui Chan1 and Ming-Shi Chang1
1Department of Biochemistry and Molecular Biology, 3Institute of Oral Medicine and
Department of Stomatology, College of Medicine, National Cheng Kung University, Tainan,
Taiwan
2Department of Medical Research and Development, Show Chwan Health Care System,
Changhua, Taiwan
Running title: IL-20 and oral cancer
Keywords: IL-20, oral cancer, inflammation
Word count: 5418
Total number of figures: 5
Total number of tables: 0
Conflict of Interest: All the authors declare no competing financial interests.
Footnotes:
Address correspondence and reprint requests to Prof. Ming-Shi Chang, Department of
Biochemistry and Molecular Biology, National Cheng Kung University, College of Medicine,
Tainan 70428, Taiwan. Tel: 886-6-235-3535 ext 5677; Fax: 886-6-274-1694; E-mail:
IL-20 and oral cancer 2
Abstract
IL-20 is a proinflammatory cytokine involved in rheumatoid arthritis, atherosclerosis, and
osteoporosis. However, little is known about the role of IL-20 in oral cancer. We explored the
function of IL-20 in the tumor progression of oral cancer. IL-20 expression levels in tumorous
and non-tumorous oral tissue specimens from 40 patients with four different stages oral cancer
were analyzed with IHC staining and RTQ-PCR. Expression of IL-20 and its receptor subunits
was higher in clinical oral tumor tissue than in non-tumorous oral tissue. The role of IL-20 was
examined in two oral cancer cell lines (OC-3 and OEC-M1). In vitro, IL-20 promoted TNF-α,
IL-1β, MCP-1, CCR4, and CXCR4, and increased proliferation, migration, ROS production,
and colony formation of oral cancer cells via activated STAT3 and AKT/JNK/ERK signals. To
evaluate the therapeutic potential of anti-IL-20 monoclonal antibody 7E for treating oral cancer,
an ex vivo tumor growth model was used. In vivo, 7E reduced tumor growth and inflammation
in oral cancer cells. In conclusion, IL-20 promoted oral tumor growth, migration, and
tumor-associated inflammation. Therefore, IL-20 may be a novel target for treating oral cancer,
and anti-IL-20 monoclonal antibody 7E may be a feasible therapeutic.
IL-20 and oral cancer 3
Introduction
With approximately 500,000 new cases annually, squamous cell carcinomas of the head
and neck (HNSCC), are one of the six most common cancers in the world (1). Oral cancer
comprises nearly 30% of all HNSCC. Of these, approximately 90% of cases are squamous cell
carcinomas (2). Oral squamous cell carcinoma (OSCC) is a major health problem worldwide,
and patients have a particularly poor 5-year survival rate (3). The staging of oral cancer is an
important step in defining the natural history and prognosis of the disease, and affects
treatment decisions. Based on the TNM (T: tumor size; N: regional nodal involvement; M:
distant metastasis) classification with various modifications, stages are determined according
to the American Joint Committee on Cancer (AJCC) and the International Union Against
Cancer (UICC) classification system for oral cancer (3). Each stage is a progression through a
primary tumor and progressively nodal, adjacent, and distant metastasis.
Several mechanisms involved in oral cancer have been extensively studied; however, the
poor prognosis may reflect an incomplete knowledge of the mechanisms underlying the
malignant progression of this cancer type. Oral cancer starts with uncontrolled cell
proliferation, and over time becomes able to multiply without limit (immortalization) (4). Next,
oral cancer cells acquire the ability to migrate from their original site, invade nearby tissue, and
metastasize to distant sites. The accumulation of changes in certain molecules results in these
progressive changes from slightly deregulated proliferation to full malignancy.
Prolonged alcohol and tobacco use, betel nut chewing, and infection with the human
papillomavirus (HPV) are known risk factors and have suggested the involvement of chronic
inflammation and oxidative stress in the development of oral cancer (5, 6). Reactive oxygen
species (ROS) are formed in the human oral cavity after they have been exposed to the above
stimulants. ROS induce DNA damage and activate intracellular signals and transcription
factors (7). These alterations in turn affect the production and function of certain molecules for
IL-20 and oral cancer 4
regulating the cell cycle, growth, differentiation, migration, invasion, and inflammation (8).
Inflammation in the tumor microenvironment has many tumor-promoting effects (9). It aids in
the proliferation and survival of malignant cells, promotes angiogenesis and metastasis,
disrupts adaptive immune responses, and alters responses to hormones and chemotherapeutic
agents (10-12). Among these agents, proinflammatory cytokines, such as IL-lβ, IL-6, and
TNF-α, are essential for regulating the immune response and may have prognostic significance
in cancer. The serum levels of IL-lβ, IL-6, and TNF-α are higher in patients with oral cancer
than in healthy persons, and increased serum levels appear to be correlated with the clinical
stage of the disease (13). Leukocyte trafficking, which is critically regulated by chemokines
and their receptors, shares many of the characteristics of tumor cell infiltration and metastasis.
Increasing evidence suggests a pivotal role for CXCL12/CXCR4 in the establishment of lymph
node and distant metastasis in OSCC (14, 15) by inducing epithelial-mesenchymal transition
(16).
A number of downstream signaling events, such as the Ras/Raf/MAPK, the STAT3, and
the PI3K/AKT/mTOR pathways, contribute to the malignant growth and metastatic potential
of OSCC (17-19). They are often persistently active in oral cancer cells.
IL-20 is a member of the IL-10 family, which includes IL-10, IL-19, IL-20, IL-22, IL-24,
and IL-26 (20), which share 18-25% amino acid identity with IL-10. IL-20 is expressed in
monocytes, epithelial cells, and endothelial cells. It acts on multiple cell types by activating a
heterodimer receptor complex of either IL-20R1/IL-20R2 or IL-22R1/IL-20R2 (21). It is also
involved in various inflammatory diseases, such as psoriasis (22, 23), rheumatoid arthritis (24,
25), atherosclerosis (26), and renal failure (27).
We previously showed (26, 28) that IL-20 not only promoted angiogenesis, but also
increased tumor vascularization. Moreover, IL-20 is regulated by hypoxia and contributes to
brain injury in an ischemic stroke model, which indicates that IL-20 is a promoting factor in the
IL-20 and oral cancer 5
inflammation-associated disease (29). Most solid tumor cells grow under hypoxic conditions,
which may induce IL-20 overexpression. In addition, HIF-1α is an independent prognostic
marker in oral squamous cell carcinoma and is important in the pathogenesis of oral cancer
(30). Little is known about the involvement of IL-20 in the pathogenesis of oral cancer.
Therefore, we studied IL-20 expression and its biological function in oral cancer cells. We also
evaluated the therapeutic effects of anti-IL-20 monoclonal antibody (mAb) 7E to alleviate or
abrogate key malignant phenotypic characteristics of oral cancer in vitro and in vivo.
IL-20 and oral cancer 6
Materials and methods
Participants
Forty patients with oral cancer (stage I, n = 10; stage II, n = 10; stage III, n = 10; stage IV,
n = 10) were enrolled in this study. Oral tumor and non-tumorous tissue from these patients was
analyzed. Non-tumorous oral tissue was taken from non-pathological areas distant from tumors
in surgical specimens and histology examinations confirmed that they were non-tumorous.
Biopsies were taken after obtaining informed consents for the study from all participants. The
study was approved by the Ethics Committee of National Cheng Kung University Hospital.
Cell lines
OC-3 cells (31), from a cell line isolated from a Taiwanese patient with OSCC, were
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum
(FBS) (Life Technologies, Rockville, MD), 2 mM/L of L-glutamine (Life Technologies), 100
μg/mL of streptomycin, and 100 units/mL of penicillin in a humidified 5% CO2 atmosphere at
37°C. OEC-M1 cells (32), from a cell line derived from the gingival epidermal carcinoma of a
Taiwanese patient, were maintained in RPMI 1640 medium.
Immunohistochemistry and immunocytochemistry
Paraffin-embedded-tissue samples were used for immunohistochemistry (IHC) staining
with anti-IL-20 (7E), anti-IL-20R1, anti-IL-20R2, or anti-IL-22R1 mAb (R&D Systems,
Minneapolis, MN) at 4°C overnight as previously described (33). Incubating paraffin tissue
sections with mouse IgG1 isotype (clone 11711; R&D Systems) instead of primary antibody
was the negative control. We used 3 μg/ml as the working concentration for each primary
antibody and for the control mouse IgG1. At least five sections from each patient's specimen
were analyzed and examined by two investigators trained in oral pathology and blinded to
patient details. Immunocytochemical staining of IL-20 and its receptors in OC-3 and OEC-M1
cells was done using the same protocol as described above.
IL-20 and oral cancer 7
Real-time quantitative polymerase chain reaction (RTQ-PCR)
To examine the oral cancer cell lines and clinical specimens, OC-3 cells, OEC-M1 cells,
oral tumor cells, and non-tumorous oral tissue specimens from 40 patients were analyzed.
Total RNA was isolated (Invitrogen, Carlsbad, CA). Reverse transcription was done with
reverse transcriptase (Clontech, Palo Alto, CA). Human IL-20, IL-20R1, IL-20R2, and
IL-22R1 expression was then amplified on a thermocycler (LC 480; Roche Diagnostics,
Indianapolis, IN), with SYBR Green (Roche Diagnostics) as the interaction agent.
Quantification analysis of mRNA was normalized with hGAPDH used as the housekeeping
gene. Relative multiples of change in mRNA expression was determined by calculating 2−��Ct.
To examine the expression of TNF-α, IL-1β, and MCP-1, OC-3 and OEC-M1 cells were
incubated with IL-20 (200 ng/ml) for the indicated times, and then total mRNA was isolated
and analyzed. The expression levels of these genes were analyzed using RTQ-PCR with
specific primers following the same protocol as described above.
Cell proliferation assay
OC-3 cells (3 × 104) and OEC-M1 cells (4 × 104) were cultured overnight and then
exposed to IL-20 (50-200 ng/ml) for 72 hours in medium containing 1% FBS. To demonstrate
the specific activity of IL-20, 7E (2 μg/ml) was added to the culture system, either alone or
together with IL-20 at a 10:1 concentration ratio (7E:IL-20). OC-3 and OEC-M1 cells
responses to IL-20 stimulation were assessed using 3H-thymidine incorporation assays. Briefly,
after 54 hours of incubation, 1 μCi of 3H-thymidine (NEN Life Sciences, Boston, MA) was
added, and cells were pulse-labeled for 18 hours. The degree of proliferation was determined as
counts per minutes, detected using a scintillation counter (Beckman Coulter, Fullerton, CA).
Cell migration assay
OC-3 and OEC-M1 cells were assayed using a 48-well chamber (modified Boyden
chamber) housing a polycarbonate filter with 8-μm pores (Nucleopore, Cabin John, MD). The
IL-20 and oral cancer 8
upper wells were loaded with OC-3 (2 × 104) or OEC-M1 (3 × 104) cells. The lower chambers
were filled with IL-20 (100 and 200 ng/ml), 7E (2 μg/ml), or IL-20 plus 7E in medium
containing 0.1% FBS. Medium with 0.1% FBS was used as a negative control. 7E against
IL-20 was used to specifically neutralize the activity of IL-20. The chambers were incubated
for 6 hours at 37°C. Cells adhering to the lower side of the filter were fixed with methanol and
stained in a Giemsa solution (Diff-Quick; Baxter Healthcare, Deerfield, IL) for counting. The
number of OC-3 and OEC-M1 cells on the lower surface of the filter was determined by
counting 12 randomly selected fields under a microscope at 100× magnification. The
experiment was done 3 times using quadruplicate wells, and migration was determined as the
mean of the total cells counted per field.
Flow cytometric analysis
We used fluorochrome, 5,6-carboxy-2,7-dichlorofluorescein diacetate (DCFH-DA) to
measure the intracellular generation of ROS. OC-3 cells (1 × 106) and OEC-M1 (1.5 × 106)
cells were stimulated by the indicated concentrations of IL-20 in serum-free medium for 30
minutes. The OC-3 and OEC-M1 cells were harvested after treatment and stained for 30
minutes at 37°C with 10 μM of DCFH-DA (Molecular Probes, Eugene, OR). After they had
been washed, the cells were kept in the dark and immediately analyzed in a cytometer
(FACSCalibur; BD Biosciences, San Jose, CA). For each analysis, 10,000 events were
recorded.
The expression of CCR4 and CXCR4 on the surface of IL-20-treated OC-3 and OEC-M1
cells was determined using a flow cytometric assay. OC-3 (1 × 106) and OEC-M1 (1.5 × 106)
cells were treated with IL-20 (100 and 200 ng/ml) for 24 hours. To demonstrate the specific
activity of IL-20, 7E (2 μg/ml) was added to the culture system, either alone or together with
IL-20. After they had been treated, the OC-3 and OEC-M1 cells were dissociated into cell
suspension using an enzyme (TrypLE; Invitrogen) and harvested for staining with anti-CCR4
IL-20 and oral cancer 9
and -CXCR4 monoclonal antibodies (BD Biosciences) at 4°C for 30 minutes. Some OC-3 and
OEC-M1 cells were also left unstained and labeled with nonspecific isotype antibodies as
controls. Subsequently, the stained cells were washed once with PBS containing 1% FBS, and
then subjected to a standard flow cytometric analysis in the cytometer.
Western blotting
OC-3 cells (5 × 105) were stimulated with IL-20 (200 ng/ml) (R&D Systems) for the
indicated time periods. Western blotting used antibodies specific for phosphorylated AKT,
JNK, ERK, and STAT3 (Cell Signaling Technology, Beverly, MA). α-Tubulin was detected
using a specific antibody (Cell Signaling Technology) as an internal control.
Colony formation
OC-3 (2500/well) and OEC-M1 (3500/well) cells were suspended in 0.5% Bacto Agar
and plated onto a layer of 1% Bacto™ Agar in medium containing 5% FBS in 6-well
tissue-culture plates (Corning, Corning, NY). The agar-containing cells were allowed to
solidify overnight at 37°C in a 5% CO2 humidified atmosphere. Additional medium with 5%
FBS with IL-20 (200 ng/ml) was overlaid on the agar, and the cells were allowed to grow
undisturbed. The culture medium was changed every 2 days. To demonstrate the specific
activity of IL-20, 7E (2 μg/ml) was added to the culture system, either alone or together with
IL-20. The cells were cultured for 10 days, fixed in methanol, and stained with Giemsa. Visible
colonies (> 50 cells) were counted with the aid of a dissecting microscope.
Oral cancer-bearing tumor model
All animal experiments were conducted according to the protocols based on the Taiwan
National Institutes of Health standards and guidelines for the care and use of experimental
animals. The research procedures were approved by the Animal Ethics Committee of National
Cheng Kung University. Eight-week-old female SCID mice were used in all experiments. The
left mammary fat pad of each mouse was subcutaneously (s.c.) injected with OC-3 cells (2 ×
IL-20 and oral cancer 10
106 cells) or OEC-M1 cells (4 × 106 cells). The mice were then randomly assigned to 3 groups
(n = 6 per group), and treated with PBS, 7E (5 mg/kg; s.c.), or mouse IgG (5 mg/kg; s.c.) every
three days for the duration of the treatment regimen. The antibody was injected (s.c.) into the
periphery of the growing tumor in tumor-bearing SCID mice. Healthy controls were not
injected with tumor cells. Fifty days after the tumor cells had been injected, the mice were
killed and their tumor tissue was harvested and weighed. The tumor tissues isolated from the
six mice in each group were fixed in 3.7% formaldehyde for H&E staining. To analyze the
expression levels of IL-20, TNF-α, IL-1β, and MCP-1, the tumor tissue was placed in PBS
solution and homogenized, and then RNA was extracted. Levels of cytokines were detected
using RTQ-PCR with specific primers as described above.
Statistical analysis
Prism 5.0 (GraphPad Software, San Diego, CA) was used for the statistical analysis. A
one-way ANOVA nonparametric test (Kruskal-Wallis test) was used to compare the data
between groups. Post hoc comparisons were done using Dunn's multiple comparison test.
Results are expressed as means ± standard deviation (SD). Significance was set at P < 0.05.
IL-20 and oral cancer 11
Results
Higher expression of IL-20 and its receptors in oral cancer
To examine whether IL-20 is involved in the pathogenesis of oral cancer, IHC staining
was used to analyze the expression levels of IL-20 in tumorous and non-tumorous oral tissue
specimens from 40 patients with oral cancer. IL-20 and its receptors were strongly stained on
tumor cells of oral tumor tissue, but only slightly stained on endothelial cells in non-tumorous
oral tissue (Fig. 1A). Furthermore, RTQ-PCR showed that transcript levels of IL-20 (Fig. 1B)
and its receptors (Fig. 1C-E) in oral tumor tissue were significantly higher than in
non-tumorous oral tissue samples. Their expression levels also correlated well with the stages
of the oral cancer (Fig. 1B-E). The expression levels of IL-20 and receptor subunits were the
highest in stage IV oral tumor tissue. These data suggested that IL-20 is involved in the
pathogenesis of oral cancer.
IL-20 increased cell proliferation, migration, and ROS production in oral cancer cells
To study the effects of IL-20 on oral cancer cells in vitro, the expression of IL-20 and its
receptors in OC-3 and OEC-M1 cells was analyzed. OC-3 cells were established from an oral
squamous cell carcinoma of a non-smoking long-term areca (betel nut) chewer (31), while
OEC-M1 is a cell line derived from gingival epidermal carcinoma of a Taiwanese patient (32).
RT-PCR and immunocytochemical staining showed that IL-20, IL-20R1, IL-20R2, and
IL-22R1 were all expressed on OC-3 and OEC-M1 cells (Fig. 2A-B) In addition, ELISA was
used to detect the endogenous IL-20 protein secreted in the conditioned media of OC-3 (373.1
pg/ml) and OEC-M1 (214.8 pg/ml) cells. This indicated that IL-20 might target cancer cells
using a paracrine or autocrine mechanism. A 3H-thymidine incorporation assay was used to
analyze the proliferation of oral cancer cells treated with IL-20. IL-20 dose-dependently
increased OC-3 and OEC-M1 cell proliferation after 72 hours of treatment (P < 0.05 compared
with the untreated controls) (Fig. 2C). To confirm the specificity of IL-20-induced proliferation
IL-20 and oral cancer 12
of OC-3 and OEC-M1 cells, anti-IL-20 mAb 7E was used to neutralize the IL-20-induced
proliferation of OC-3 and OEC-M1 cells. 7E inhibited IL-20-induced cell proliferation (Fig.
2C). To determine whether IL-20 affected cell migration in OC-3 and OEC-M1 cells, a Boyden
chamber assay was used to evaluate the migration ability (Fig. 2D). IL-20 significantly
promoted OC-3 and OEC-M1 cell migration (P < 0.05 compared with the untreated controls),
which was inhibited by 7E (Fig. 2D). Because oxidative stress is vital in the malignant
transformation of oral cancer, we also analyzed the effect of IL-20 on ROS generation in OC-3
and OEC-M1 cells. IL-20 significantly and dose-dependently increased intracellular ROS
production in OC-3 and OEC-M1 cells (P < 0.05 compared with the untreated controls), which
was inhibited by 7E (Fig. 2E). These results suggested that IL-20 increased proliferation,
migration, and ROS production in oral cancer cells, and was critical in the progression of oral
tumor growth.
IL-20 upregulated TNF-α, IL-1β, MCP-1, CCR4, and CXCR4 in oral cancer cells
The molecular pathways of cancer-related inflammation were revealed, which allowed us
to identify new target molecules that might lead to improved diagnosis and treatment.
Therefore, we investigated whether IL-20 is involved in tumor-associated inflammation. We
incubated OC-3 and OEC-M1 cells with IL-20 and used RTQ-PCR to analyze the expression of
proinflammatory cytokines, chemokines, and chemokine receptors. The TNF-α, IL-1β, and
MCP-1 expression significantly increased in IL-20-treated OC-3 (Fig. 3A-C) and OEC-M1
cells (data not shown); however, the expression of other inflammatory mediators, namely, IL-6,
IL-8, MMP-2, MMP-7, and MMP-9, was not affected (data not shown). IL-20 treatment
significantly induced CCR4 and CXCR4 expression on the surface of OC-3 cells (Fig. 3D-E).
Although flow cytometric analysis showed that IL-20 increased CCR4 and CXCR4 expression
on the surface of OEC-M1 cells, they showed no significant difference when the data were
analyzed using ANOVA.
IL-20 and oral cancer 13
To confirm that IL-20 specifically induced their expression, the OC-3 cells were treated
with IL-20 plus 7E. Flowcytometric analysis showed that 7E had significantly neutralized
CCR4 and CXCR4 expression in co-treated OC-3 cells (Fig. 3D-E). In addition, we found that
IL-20 expression was significantly correlated with CXCR4 expression on the oral tumor tissue
of patients with stage IV cancer (data not shown). To clarify the mechanism that IL-20 uses to
promote tumor progression, the signal molecules of JNK, STAT3, ERK, and AKT were
assessed in IL-20-stimulated OC-3 cells. Western blotting showed that IL-20 promoted the
activation of JNK, STAT3, ERK, and AKT (Fig. 3F). These results indicated that IL-20
induced inflammatory mediators in oral cancer, triggered proliferation-associated signals, and
was a promoting factor for tumor growth.
IL-20 promoted colony formation of OC-3 and OEC-M1 cells
Neoplastically transformed cells show reduced requirements for extracellular
growth-promoting factors, and they are not restricted by cell-cell contact.
Anchorage-independent growth is one of the hallmarks of the malignant transformation of cells.
Therefore, we used a soft agar colony formation assay to monitor the ability of IL-20 in the
anchorage-independent growth of OC-3 and OEC-M1 cells. IL-20 significantly stimulated
OC-3 and OEC-M1 cells to form more colonies than the controls formed, which was inhibited
by 7E (Fig. 4A-B). OC-3 cells co-treated with IL-20 and 7E formed significantly fewer and
smaller (Fig. 4C) colonies in soft agar than did cells treated with IL-20 alone. These results
suggest a significant role for IL-20 in the malignant transformation of oral cancer cells.
7E suppressed in vivo tumor growth and reduced inflammation within the tumor
microenvironment
IL-20 was highly expressed in oral cancer tissue, and it increased oral tumor growth and
inflammation in vitro. 7E has shown specificity and neutralization activity in vitro and in
vivo.(24, 28, 33) Therefore, we analyzed whether 7E reduced tumor growth in vivo. OC-3 cells
IL-20 and oral cancer 14
were injected into the left mammary fat pads of SCID mice. One day later, the mice were
injected (s.c.) with PBS, 7E (5 mg/kg), or mIgG (5 mg/kg) (n = 6 per group) every 3 days for 50
days. Fifty days after they had been injected with OC-3 cells, all the mice were killed and their
tumors were isolated. Tumors were significantly smaller (Fig. 5A) and weighed significantly
less (Fig. 5B) in the 7E-treated group than in the control mIgG- and PBS-treated groups. H&E
staining showed that immune cell infiltration was reduced in the tumor mass of the 7E
treated-group compared with the mIgG-treated control group (Fig. 5C). Tumor tissue from
each group was then isolated and homogenized to extract RNA. RTQ-PCR assays showed that
IL-20 levels in the tumor were lower in the 7E-treated group than in the mIgG-treated group
(Fig. 5D). In addition, the expression of the inflammation mediators TNF-α, IL-1β, and
MCP-1 was significantly lower in the 7E-treated group than in the mIgG-treated group (Fig.
5E-G). Furthermore, we used OEC-M1 cells to confirm the effect of 7E in tumor-bearing SCID
mice and obtained similar results (Supplemental Fig. 1). These results indicated that 7E
suppressed tumor growth in vivo by reducing IL-20 expression, decreasing other
proinflammatory cytokines, and inhibiting immune cell infiltration.
IL-20 and oral cancer 15
Discussion
We found that both IL-20 and its receptors were highly expressed in primary,
nodal-involved, and distantly metastatic oral tumor tissue. IL-20 expression was correlated
with the tumor stages in oral cancer patients. All IL-20 receptor subunits were expressed in our
clinical specimens, which suggested that both autocrine and paracrine effects of IL-20 on oral
tumors and contributed to the pathogenesis of oral cancer.
IL-20 directly affected oral cancer cell proliferation by activating proliferation-associated
signals such as JNK, ERK, and STAT3, and migration by activating migration-associated
signals such JNK and ERK. IL-20 also provided a microenvironment for tumor growth and
metastasis by inducing ROS and proinflammatory cytokines, which are essential for the
malignant process from normal epithelium to invasive oral cancer (34). ROS may increase the
inflammatory responses mediated by activating signaling molecules such as ERK and JNK,
and transcription factors like NF-κB. NF-κB regulates many proteins involved in tumor
initiation, tumor expansion, and metastasis promotion in many types of cancers, including oral
cancer (35, 36).
A variety of cytokines, such as IL-1, IL-6, and TNF-α, as well as chemokines, such as
IL-8, CXCL5, CXCL6, CXCL7, CCL5, and CCL20, were upregulated in progressive oral
cancer cells (6, 37, 38) and in patients with oral cancer (13). The effects of CCL and CXCL
chemokines are mediated via their CCR and CXCR receptors. IL-20-treated OC-3 and
OEC-M1 cells increased TNF-α and IL-1β production, which are potent proinflammatory
cytokines for the growth, metastasis, and immune evasion of oral tumors. We also found that
IL-20 induced MCP-1 and CCR4 expression in OC-3 cells. MCP-1(39, 40) and CCR4 (41, 42)
have been associated with several cancers. Therefore, IL-20 may promote leukocyte trafficking,
which augments inflammation, tumor cell infiltration, and metastasis in oral tumors, by such a
novel, undefined mechanism. Several studies (43, 44) have associated CXCR4 and oral cancer.
IL-20 and oral cancer 16
IL-20 induced more CXCR4 expression on the surface of IL-20-treated OC-3 cells than of the
untreated control group. The involvement of CXCR4 signaling in OSCC was mediated by the
activation of both the ERK and the AKT/PKB pathways (45). Therefore, IL-20-induced
activation of ERK and AKT may cross-link to amplify the CXCR4 signaling for the
chemotaxis of oral cancer cells. 7E treatment to inhibit IL-20-induced CXCR4 expression may
be a potent anti-metastatic therapy against lymph-node and distant metastases in cases of
CXCR4-related OSCC. IL-20 increased the anchorage-independent growth of OC-3 and
OEC-M1 cells, which confirmed that IL-20 was potently involved in the malignant
transformation of oral cells.
IL-20 was upregulated in the tumor tissue of oral cancer patients. In our mouse tumor
model using OC-3 and OEC-M1 cells, we confirmed that IL-20 was highly expressed in the
tumor mass, which is consistent with our clinical findings. IL-20 is a hypoxia-inducible gene
and the hypoxia response element (HRE) has been identified in IL-20 promoter (29). Areca
(betel) nut extract modulates a signaling cascade that induces HIF-1α expression in oral cancer
cells (46). HIF-1α is an independent prognostic marker in OSCC (30). Therefore, one possible
mechanism upregulating IL-20 in the tumor may be the response of oral cancer cells to hypoxia.
HIF-1α binds to the hypoxia response element on IL-20 promoter and activates IL-20
expression. Human HPV infection is a known risk factor in the development of oral cancer (1,
5). Whether HPV regulates IL-20 expression in the pathogenesis of oral cancer is not well
understood. Additional investigations of the regulation between IL-20 and HPV infection are
required.
7E suppressed OC-3 and OEC-M1 tumor growth and tumor weight in vivo. The inhibition
of tumor growth and tumor size in 7E-treated mice correlated with lower IL-20 expression,
which indicated that IL-20 was involved in the progression of oral cancer by regulating tumor
cell proliferation in vivo.
IL-20 and oral cancer 17
We hypothesize a working model of IL-20 in oral cancer progression. Oral cancer cells or
infiltrated immune cells secrete a large amount of IL-20, which promotes tumor cell
proliferation by phosphorylating ERK, JNK, AKT, and STAT3 in an autocrine/paracrine
manner. The overexpressed IL-20 stimulates ROS production in tumor cells. IL-20-induced
production of proinflammatory cytokines and ROS by tumor cells amplify local inflammation
within the tumor microenvironment. Eventually, all of these tumor-promoting effects
contribute to the proliferation and survival of malignant cells, angiogenesis, metastasis, and the
impairment of immune responses. In addition, the chemoattractant activity of IL-20 further
increases immune cell infiltration, which results in IL-20 overexpression, which, in turn, forms
a positive loop to oral cancer progression. 7E suppresses IL-20-induced tumor growth and
local inflammation in vitro and in vivo, which supports our hypothesis.
We previously showed that IL-20 was induced in response to hypoxia; promoted
angiogenesis in endothelial cells; induced IL-6, IL-8, and MCP-1 expression in several types of
cells; and was a chemoattractant for neutrophils. In the present study, we showed that IL-20
increased the proliferation and migration of oral cancer cells. IL-20 also induced the expression
of TNF-α, IL-1β, and MCP-1, as well as the production of CCR4 and CXCR4, on oral cancer
cells. These properties of IL-20 provide evidence that IL-20 is involved in many phases of
tumor progression and nurtures a microenvironment for tumor cells.
In summary, our findings indicate that IL-20 is involved in oral cancer progression. IL-20
not only directly increased the proliferation, anchorage-independent growth, and migration of
cancer cells, but also generated a microenvironment that facilitated tumor progression by
inducing the production of ROS and of several proinflammatory cytokines and chemokine
receptors. We conclude that IL-20 is a novel target for pharmacological intervention for
inhibiting the tumor growth and metastasis of oral cancer.
IL-20 and oral cancer 18
References
1. Parkin DM, Bray F, Ferlay J, & Pisani P (2005) Global cancer statistics, 2002. CA
Cancer J Clin 55(2):74-108.
2. Cooper JS, et al. (2009) National Cancer Database report on cancer of the head and
neck: 10-year update. Head Neck 31(6):748-758.
3. Edge SB, et al. (2010) AJCC Cancer Staging Manual. 7th ed. Springer: New York.
4. Hanahan D & Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70.
5. Bagan JV & Scully C (2008) Recent advances in Oral Oncology 2007: epidemiology,
aetiopathogenesis, diagnosis and prognostication. Oral Oncol 44(2):103-108.
6. Jeng JH, et al. (2003) Roles of keratinocyte inflammation in oral cancer: regulating the
prostaglandin E2, interleukin-6 and TNF-alpha production of oral epithelial cells by
areca nut extract and arecoline. Carcinogenesis 24(8):1301-1315.
7. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E, & Moreno-Sanchez R (The
causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic
transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med
31(2):145-170.
8. Lerner L, Weiner D, Katz R, Reznick AZ, & Pollack S (2009) Increased
pro-inflammatory activity and impairment of human monocyte differentiation induced
by in vitro exposure to cigarette smoke. J Physiol Pharmacol 60 Suppl 5:81-86.
9. Mantovani A, Allavena P, Sica A, & Balkwill F (2008) Cancer-related inflammation.
Nature 454(7203):436-444.
10. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, & Graeve L (1998)
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.
Biochem J 334 ( Pt 2):297-314.
11. Nicolini A, Carpi A, & Rossi G (2006) Cytokines in breast cancer. Cytokine Growth
IL-20 and oral cancer 19
Factor Rev 17(5):325-337.
12. Slettenaar VI & Wilson JL (2006) The chemokine network: a target in cancer biology?
Adv Drug Deliv Rev 58(8):962-974.
13. Jablonska E, Piotrowski L, & Grabowska Z (1997) Serum Levels of IL-1b, IL-6,
TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer. Pathol Oncol Res
3(2):126-129.
14. Uchida D, et al. (2004) Acquisition of lymph node, but not distant metastatic potentials,
by the overexpression of CXCR4 in human oral squamous cell carcinoma. Lab Invest
84(12):1538-1546.
15. Uchida D, et al. (2007) Involvement of an autocrine stromal cell derived
factor-1/CXCR4 system on the distant metastasis of human oral squamous cell
carcinoma. Mol Cancer Res 5(7):685-694.
16. Onoue T, et al. (2006) Epithelial-mesenchymal transition induced by the stromal
cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol
29(5):1133-1138.
17. Yang LC, Yang SH, Tai KW, Chou MY, & Yang JJ (2004) MEK inhibition enhances
bleomycin A5-induced apoptosis in an oral cancer cell line: signaling mechanisms and
therapeutic opportunities. J Oral Pathol Med 33(1):37-45.
18. Siavash H, Nikitakis NG, & Sauk JJ (2004) Signal transducers and activators of
transcription: insights into the molecular basis of oral cancer. Crit Rev Oral Biol Med
15(5):298-307.
19. Watanabe S, et al. (2009) Activation of PI3K-AKT pathway in oral epithelial dysplasia
and early cancer of tongue. Bull Tokyo Dent Coll 50(3):125-133.
20. Pestka S, et al. (2004) Interleukin-10 and related cytokines and receptors. Annual
review of immunology 22:929-979.
IL-20 and oral cancer 20
21. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, & Renauld JC (2001) Cutting edge:
STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two
types. J Immunol 167(7):3545-3549.
22. Blumberg H, et al. (2001) Interleukin 20: discovery, receptor identification, and role in
epidermal function. Cell 104(1):9-19.
23. Wei CC, et al. (2005) Detection of IL-20 and its receptors on psoriatic skin. Clin
Immunol 117(1):65-72.
24. Hsu YH, et al. (2006) Function of interleukin-20 as a proinflammatory molecule in
rheumatoid and experimental arthritis. Arthritis and rheumatism 54(9):2722-2733.
25. Hsu YH & Chang MS (2010) Interleukin-20 antibody is a potential therapeutic agent
for experimental arthritis. Arthritis and rheumatism 62(11):3311-3321.
26. Chen WY, Cheng BC, Jiang MJ, Hsieh MY, & Chang MS (2006) IL-20 is expressed in
atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient
mice. Arterioscler Thromb Vasc Biol 26(9):2090-2095.
27. Li HH, et al. (2008) Interleukin-20 induced cell death in renal epithelial cells and was
associated with acute renal failure. Genes Immun 9(5):395-404.
28. Hsieh MY, et al. (2006) Interleukin-20 promotes angiogenesis in a direct and indirect
manner. Genes Immun 7(3):234-242.
29. Chen WY & Chang MS (2009) IL-20 is regulated by hypoxia-inducible factor and
up-regulated after experimental ischemic stroke. J Immunol 182(8):5003-5012.
30. Eckert AW, et al. (2010) HIF-1alpha is a prognostic marker in oral squamous cell
carcinomas. Int J Biol Markers 25(2):87-92.
31. Lin SC, et al. (2004) Establishment of OC3 oral carcinoma cell line and identification
of NF-kappa B activation responses to areca nut extract. J Oral Pathol Med
33(2):79-86.
IL-20 and oral cancer 21
32. Yang CY & Meng CL (1994) Regulation of PG synthase by EGF and PDGF in human
oral, breast, stomach, and fibrosarcoma cancer cell lines. J Dent Res 73(8):1407-1415.
33. Hsu YH, et al. (2012) Anti-IL-20 monoclonal antibody suppresses breast cancer
progression and bone osteolysis in murine models. J Immunol 188(4):1981-1991.
34. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, & Gorgoulis VG (2007)
Advances in the biology of oral cancer. Oral Oncol 43(6):523-534.
35. Nagini S, Letchoumy PV, A T, & Cr R (2009) Of humans and hamsters: a comparative
evaluation of carcinogen activation, DNA damage, cell proliferation, apoptosis,
invasion, and angiogenesis in oral cancer patients and hamster buccal pouch
carcinomas. Oral Oncol 45(6):e31-37.
36. Karin M & Greten FR (2005) NF-kappaB: linking inflammation and immunity to
cancer development and progression. Nat Rev Immunol 5(10):749-759.
37. Chuang JY, et al. (2009) CCL5/CCR5 axis promotes the motility of human oral cancer
cells. J Cell Physiol 220(2):418-426.
38. Hunter KD, et al. (2006) Divergent routes to oral cancer. Cancer Res
66(15):7405-7413.
39. Mestdagt M, et al. (2006) Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in
human breast cancer cells. Int J Cancer 118(1):35-42.
40. Monti P, et al. (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer
progression: regulation of expression and potential mechanisms of antimalignant
activity. Cancer Res 63(21):7451-7461.
41. Olkhanud PB, et al. (2009) Breast cancer lung metastasis requires expression of
chemokine receptor CCR4 and regulatory T cells. Cancer Res 69(14):5996-6004.
42. Lee JH, et al. (2009) The chemokine receptor CCR4 is expressed and associated with a
poor prognosis in patients with gastric cancer. Ann Surg 249(6):933-941.
IL-20 and oral cancer 22
43. Takabayashi T, et al. (2009) Lipopolysaccharides increase the amount of CXCR4, and
modulate the morphology and invasive activity of oral cancer cells in a
CXCL12-dependent manner. Oral Oncol 45(11):968-973.
44. Teng YH, et al. (2009) Contribution of genetic polymorphisms of stromal cell-derived
factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic
development of oral cancer. Head Neck 31(10):1282-1288.
45. Uchida D, et al. (2003) Possible role of stromal-cell-derived factor-1/CXCR4 signaling
on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res
290(2):289-302.
46. Lu HH, et al. (2010) Areca nut extract induced oxidative stress and upregulated
hypoxia inducing factor leading to autophagy in oral cancer cells. Autophagy
6(6):725-737.
IL-20 and oral cancer 23
Figure Legends
Figure 1. Higher expression of IL-20 and its receptors in oral cancer. Surgical biopsy
samples from 40 patients with oral cancer were collected. Oral tumor and non-tumorous tissue
from 40 patients was analyzed. (A) IHC staining showed that IL-20 and its receptors were
strongly stained in four different stages of oral tumor samples but only slightly stained on
endothelial cells in non-tumorous oral tissue samples (stage I, n = 10; stage II, n = 10; stage III,
n = 10; stage IV, n = 10). (B-E) The mRNA of the oral tissues was isolated for real-time
quantitative polymerase chain reaction (RTQ-PCR) analysis using IL-20-, IL-20R1-, IL-20R2-,
and IL-22R1-specific primers. Quantification analysis of mRNA was normalized with
hGAPDH as the housekeeping control gene. Differences between the oral tumor and
non-tumorous oral tissue are statistically significant. * = P < 0.05, ** = P < 0.01 versus
non-tumorous oral tissue controls. All experiments were done 3 times with similar results. Data
are from a representative experiment.
Figure 2. IL-20 increased proliferation, migration, and ROS production in oral cancer
cells. (A) The expression of IL-20 and its receptors in OC-3 and OEC-M1 cells was analyzed
using RT-PCR with specific primers. (B) IHC staining showed that IL-20 and its receptors,
IL-20R1, IL-20R2, and IL-22R1, were expressed in OC-3 and OEC-M1 cells. (C) OC-3 (3 ×
104) and OEC-M1 (4 × 104) cells were cultured for 72 hours in 1% FBS with or without IL-20
protein (50-200 ng/ml). Cell proliferation was determined using a 3H-thymidine incorporation
assay. 7E against IL-20 (2 μg/ml) was used to specifically neutralize the proliferative activity
of IL-20. * = P < 0.05 versus untreated controls. # = P < 0.05 versus treatment with IL-20 alone.
Values are means ± standard deviation of triplicate experiments. (D) OC-3 (2 × 104) and
OEC-M1 (3 × 104) cells were incubated for 6 hours in medium containing 0.1% FBS with
IL-20 (100-200 ng/ml), 7E (2 μg/ml), or IL-20 plus 7E. Medium alone was used as a negative
IL-20 and oral cancer 24
control. 7E against IL-20 (2 μg/ml) was used to inhibit the activity of IL-20. Cell migration was
evaluated using a modified Boyden chamber assay. * = P < 0.05 versus untreated controls
(medium alone). # = P < 0.05 versus treatment with IL-20 alone. Values are means ± standard
deviation of triplicate experiments. (E) OC-3 and OEC-M1 cells were treated with IL-20 for
the indicated concentrations in serum-free medium for 30 minutes, and ROS generation was
measured using flow cytometry. * = P < 0.05 versus untreated controls. # = P < 0.05 versus
treatment with IL-20 alone. Values are means ± standard deviation of triplicate experiments.
Figure 3. IL-20 upregulated TNF-α, IL-1β, MCP-1, CCR4, CXCR4, and activated
intracellular signaling in oral cancer cells. (A-C) OC-3 cells were treated with IL-20 (200
ng/ml) for the indicated times, and the expression levels of TNF-α, IL-1β, and MCP-1 were
analyzed using RTQ-PCR with specific primers. * = P < 0.05 versus untreated controls. All
experiments were done 3 times with similar results. Data are from a representative experiment.
(D-E) OC-3 cells were treated with IL-20 in the indicated concentrations in DMEM for 24
hours. Cells were dissociated into a single cell suspension and harvested for flow cytometry
using anti-CCR4 and anti-CXCR4 monoclonal antibody. * = P < 0.05 versus untreated controls.
# = P < 0.05 versus treatment with IL-20 alone. Values are means ± standard deviation of
triplicate experiments. (F) OC-3 cells (5 × 105) were incubated with IL-20 (200 ng/ml) for the
indicated time periods, and then cell lysates were collected and analyzed using immunoblotting
with specific antibodies against phospho-JNK, phospho-STAT3, phospho-ERK, and
phospho-AKT. α-Tubulin antibody was used as an internal control. Results are representative
of 3 independent experiments.
Figure 4. IL-20 promoted colony formation in vitro. (A-B) OC-3 (2500/well) and OEC-M1
(3500/well) cells were incubated with IL-20 for 10 days, and then a colony-formation assay
was done. The culture medium was changed every 2 days. IL-20 significantly increased the
colony-formation ability of oral cancer cells. 7E (2 μg/ml) was used to inhibit the activity of
IL-20 and oral cancer 25
IL-20. * = P < 0.05 versus untreated controls. # = P < 0.05 versus treatment with IL-20 alone.
Values are means ± standard deviation of triplicate experiments. (C) IL-20 also increased the
size of colonies in a soft agar assay. Representative photos are shown for each group.
Figure 5. Anti-IL-20 mAb treatment suppressed tumor growth in vivo. OC-3 cells (2 × 106)
were injected (s.c.) into the mammary fat pads of SCID mice. One day later, the mice were
injected (s.c.) with PBS, 7E (5 mg/kg), and mIgG (5 mg/kg) (n = 6 per group) every 3 days for
50 days. (A) Tumor size was measured using a vernier caliper. * = P < 0.05 versus mIgG
controls. ** = P < 0.01 versus mIgG controls. (B) Mice were killed 50 days after they had been
injected with OC-3 cells, and their tumors were collected and weighed. * = P < 0.05 versus
mIgG controls. (C) Tumor sections from each group were stained with hematoxylin and eosin
(magnification: 200×). Representative photos are shown for each group. (D-G) Tumor tissue
samples from each group (n = 6) were isolated at the end of the experiment. The expression of
IL-20, TNF-α, IL-1β, and MCP-1 in the tumor tissue was analyzed using RTQ-PCR with
specific primers. * = P < 0.05 versus mIgG controls. Results are from a representative
experiment. All experiments were done 3 times. Values are means ± standard error of the
mean.
�����������
�������
��������